| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/10/2003 | CN1441773A Cyclohexylamine derivative as subtype selective NMDA receptor Antagonists |
| 09/10/2003 | CN1441704A Medium milling |
| 09/10/2003 | CN1441677A Combined use of anti-cytokine antibodies or antagonists and anti-CD2O for treatment of B cell lymphoma |
| 09/10/2003 | CN1441676A Method of treatment using ligand-immunogen conjugates |
| 09/10/2003 | CN1441675A Compositions and methods for achieving immune suppression |
| 09/10/2003 | CN1441672A Methods for treatment of inflammatory diseases |
| 09/10/2003 | CN1441666A Macromolecular drug complexes and compositions containing same |
| 09/10/2003 | CN1440816A Improvement for diagnosis and/or therapeutic agnet and its relative improvement |
| 09/10/2003 | CN1440814A Specific HIV RNA degrading agent and its prepn |
| 09/09/2003 | US6617450 P-glycoproteins and uses thereof |
| 09/09/2003 | US6617440 Isolated polynucleotide that promotes transcription; gene expression inhibition; used for engineering animals with increased lean meat and promoting muscle growth; treating muscular disorders |
| 09/09/2003 | US6617361 Protocol for prevention of Alzheimer's disease involves stimulating implicit memory; psychotherapeutic or psychological supports; stimulating explicit memory; transfers learned behavior into the implicit memory. |
| 09/09/2003 | US6617358 Also bis(optionally chloro- or fluoro-substitutedphenyl)alkylcarboxy acids and esters |
| 09/09/2003 | US6617355 Treating asthma by preventing and/or accomodating S-nitrosothiol breakdown |
| 09/09/2003 | US6617354 Method of stabilizing and potentiating the action of anti-angiogenic substances |
| 09/09/2003 | US6617345 Cyclooxygenase-2 inhibitor is (5-bromo-2-(4-fluorophenyl )-3-(4-(methylsulfonyl)phey)-thiophene), N-(2-(cyclohexyloxy 4-nitrophenyl)-methanesulfonamide), meloxicam, flosulide or cyclic substituted phenyl sulfones or sulfonamides |
| 09/09/2003 | US6617306 Therapeutic agent is conjugated to the carrier via a biodegradable disulfide bond. |
| 09/09/2003 | US6617151 Method of closing a cell containment device with a wet seal |
| 09/09/2003 | US6617129 Isolated nucleic acid; prostate-specific gene therapy method; diagnosis and treatment of prostate cancer |
| 09/09/2003 | US6617122 Contacting a compound with a polypeptide, in the presence of adenosine triphosphate (ATP) and detecting its binding or hydrolysis of ATP; use in treatment of coronary artery disease |
| 09/09/2003 | US6617102 Screening for a bioactive agent capable of interfering with the binding of a protein; use in diagnosis and treatment of cancer |
| 09/09/2003 | US6616941 Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof |
| 09/09/2003 | US6616939 Lactose or glucose and a mineral supplement ensuring restoration of digestive losses; efficient quantity of soluble vegetable proteins and vegetable lipids ensuring suitable appropriate energy intake. |
| 09/09/2003 | US6616938 Method of making chewing gum containing colloidal bismuth subcitrate |
| 09/09/2003 | US6616933 Excitatory amino acid inhibitors for treating sensitive skins |
| 09/09/2003 | US6616932 Liquid pharmaceutical for oral delivery |
| 09/09/2003 | US6616925 Combined preparation for the treatment of neoplasic diseases or of infectious diseases |
| 09/09/2003 | US6616913 Composition and method for treatment of otitis media |
| 09/09/2003 | US6616591 Radioactive compositions and methods of use thereof |
| 09/09/2003 | CA2138026C Novel 1,4-dihydroquinoxaline-2,3-diones and uses therefor as glycine receptor antagonists |
| 09/04/2003 | WO2003073107A2 Neuropeptide receptor and uses thereof |
| 09/04/2003 | WO2003073062A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 09/04/2003 | WO2003072802A2 Carboxyfullerenes and methods of use thereof |
| 09/04/2003 | WO2003072801A2 Compositions and method for regulation of calcium-dependent signalling in brain |
| 09/04/2003 | WO2003072787A2 Method for detection of leptin receptor ligands |
| 09/04/2003 | WO2003072740A2 Novel type-1 cytokine receptor glm-r |
| 09/04/2003 | WO2003072737A2 Biological inhibitions induced by contact inhibitory factor |
| 09/04/2003 | WO2003072735A2 Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels |
| 09/04/2003 | WO2003072591A1 Trpm-2 antisense therapy using an oligonucleotide having 2'-o-(2-methoxyl)ethyl modifications |
| 09/04/2003 | WO2003072577A1 Thiazole derivatives as npy receptor antagonists |
| 09/04/2003 | WO2003072572A1 Beta3-adrenergic receptor agonists |
| 09/04/2003 | WO2003072556A1 Glutaminyl based dpiv inhibitors |
| 09/04/2003 | WO2003072549A1 Farnesyl protein transferase inhibitors as antitumor agents |
| 09/04/2003 | WO2003072539A1 Phenethanolamine derivatives for treatment of respiratory diseases |
| 09/04/2003 | WO2003072196A1 Lower esophagus tissue modifier |
| 09/04/2003 | WO2003072159A1 N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 09/04/2003 | WO2003072138A1 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents |
| 09/04/2003 | WO2003072137A1 Combinations of (a) an atp- competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents |
| 09/04/2003 | WO2003072136A1 Antihypertensive compositions and uses thereof |
| 09/04/2003 | WO2003072135A2 Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
| 09/04/2003 | WO2003072113A1 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound |
| 09/04/2003 | WO2003072112A1 'long'-'acting' injectable parasiticidal composition |
| 09/04/2003 | WO2003072111A2 Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression |
| 09/04/2003 | WO2003072110A1 Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases |
| 09/04/2003 | WO2003072106A2 Use of tyrosine kinase inhibitors for treating substance use disorders |
| 09/04/2003 | WO2003072098A1 Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase |
| 09/04/2003 | WO2003072097A1 Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases |
| 09/04/2003 | WO2003072096A1 Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa |
| 09/04/2003 | WO2003072094A1 Ambroxol for treating painful conditions in the mouth and pharyngeal cavity |
| 09/04/2003 | WO2003072091A1 Therapeutic methods for acute myeloid leukemia |
| 09/04/2003 | WO2003072090A2 Use of tyrosine kinase inhibitors for treating cns disorders |
| 09/04/2003 | WO2003072061A2 Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy |
| 09/04/2003 | WO2003072056A2 Intranasal administration of mc4-r agonists |
| 09/04/2003 | WO2003072048A2 Symptomatic relief of gastrointestinal disorders |
| 09/04/2003 | WO2003072040A2 Administration of agents for the treatment of inflammation |
| 09/04/2003 | WO2003072029A2 Methods of extending corneal graft survival |
| 09/04/2003 | WO2003072026A2 Method of reducing and treating uvb-induced immunosuppression |
| 09/04/2003 | WO2003071933A2 Novel compositions and methods for cancer |
| 09/04/2003 | WO2003071922A2 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| 09/04/2003 | WO2003071884A1 Compound containing creatine, an acid component and/or a complexing agent |
| 09/04/2003 | WO2003064451A3 MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE |
| 09/04/2003 | WO2003063840A3 Transmucosal delivery of proton pump inhibitors |
| 09/04/2003 | WO2003053224A3 Novel compositions and methods for cancer |
| 09/04/2003 | WO2003051302A3 Methods and compositions for treatment of central nervous system disorders |
| 09/04/2003 | WO2003048120A3 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
| 09/04/2003 | WO2003045991A3 Complement c3 precursor biopolymer markers predictive of alzheimers disease |
| 09/04/2003 | WO2003033681A3 Composition comprising a lactobacillus pentosus strain and uses thereof |
| 09/04/2003 | WO2003032961A3 Methods for preventing and treating bone loss with steroid compounds |
| 09/04/2003 | WO2003030922A3 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis |
| 09/04/2003 | WO2003028730A3 Pharmaceutical combinations of pde-v inhibitors and other agents |
| 09/04/2003 | WO2003024967A3 Indolizines as kinase protein inhibitors |
| 09/04/2003 | WO2003024488A3 Combination of a pde inhibitor and a leukotriene receptor antagonist |
| 09/04/2003 | WO2003005967A3 Dual release levodopa ethyl ester and decarboxylase in controlled release core |
| 09/04/2003 | WO2002097395A3 P-cadherin as a target for anti-cancer therapy |
| 09/04/2003 | WO2002083858A8 Methods to inhibit viral replication |
| 09/04/2003 | WO2002079238A3 Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis |
| 09/04/2003 | WO2002072127A3 Modulation of smooth muscle cell proliferation by vegf-x or antagonists thereof |
| 09/04/2003 | WO2002068387A8 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 09/04/2003 | WO2002068058A3 Dapd combination therapy with imdph inhibitors such as ribavirin or mycophenolic acid |
| 09/04/2003 | WO2002066014A3 Cubic liquid crystalline compositions and methods for their preparation |
| 09/04/2003 | WO2002064792A3 Molecules for disease detection and treatment |
| 09/04/2003 | WO2002055698A3 Transcriptional mediators of blood vessel development and endothelial differentiation |
| 09/04/2003 | WO2002046426A3 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor |
| 09/04/2003 | WO2002045708A3 Use of zwitterionic polysaccharides for the specific modulation of immune processes |
| 09/04/2003 | WO2002020769A9 Human and mouse targeting peptides identified by phage display |
| 09/04/2003 | WO2002015892A3 Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors |
| 09/04/2003 | WO2002009760A9 Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure |
| 09/04/2003 | WO2002008456A3 Method for identifying metastatic tumor cells |
| 09/04/2003 | WO2002003977A3 Combinations of statins, estrogenic agents and optionally estrogens |
| 09/04/2003 | WO2001086002A3 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis |